The clinical world premiere is highlighted in Nature’s 2018 September issue. An article detailing the clinical trial INDYGO and the technology being developed to treat glioblastomas is published in a special issue of journal (https://www.nature.com/articles/d41586-018-06713-6)
The enrollment phase of the clinical trial INDYGO is successfully completed, after only one year. During this study sponsored by the University Hospital of Lille (France) and with Pr. N. Reyns as the Principal Investigator, 10 patients included from may 2017 to June 2018 have been treated with the Hemerion’s technology.
The Hemerion drug-device combination product is presented during the plenary session of annual congress of the European Association of the Neurosurgery Societies in Brussels (Be). First usability endpoints successfully collected during the Phase I INDYGO are reported to the European’s neurosurgeons community.
M. Vermandel becomes the first ever non-US resident of being the recipient of the ASLMS research grant (American Society of Lasers in Surgery and Medicine) for his work on drugs and laser technologies combination. ASLMS was founded in 1980 and is the world’s largest professional organization dedicated to the field of medical laser.
The photonic therapy is further improved with a light power regimen study that leads to better tolerance.
Hemerion Therapeutics is founded by the scientists and inventors of the technology, among them M. Vermandel, C. Dupont, N. Reyns, S. Mordon and M. Andraud gather deep scientific how-know and entrepreneurship skills to lead the company. In the mean time, Hemerion is awarded the French Tech Label that recognizes high potential start-up companies.